AI Designs First Inhaled Drug Candidate to Target Pulmonary Fibrosis
Insilico Medicine's AI-generated TNIK inhibitor enters Phase 1 trials for pulmonary fibrosis, signaling a new era in drug discovery.
2859 articles in this topic
Insilico Medicine's AI-generated TNIK inhibitor enters Phase 1 trials for pulmonary fibrosis, signaling a new era in drug discovery.
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
A Phase 1b trial shows a daily probiotic capsule may restore immunotherapy response in advanced melanoma patients who had stopped responding.
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
A new GLP-1 therapy engineered to cross the blood-brain barrier enters Phase II trials, targeting cognitive decline in Parkinson's and Alzheimer's.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Matter Bio files first IND for Listeria-based therapy targeting pancreatic cancer, merging oncology and longevity science.
A unified mathematical model shows stem cell division rates โ not methylation errors โ explain why longer-lived species age more slowly.
From refillable eye implants to suprachoroidal injections, next-gen delivery platforms are slashing treatment burden for AMD and diabetic eye disease.
A new PNAS study reveals how mitochondrial free radicals trigger the ATM-CHK2 DNA damage pathway to coordinate three key steps of mitophagy.
Scientists identify a ZBP1-RIPK1 molecular axis that detects oxidized mitochondrial DNA and ignites brain inflammation in Alzheimer's disease.
A muscle-secreted protein boosted by exercise declines with age โ restoring it in old mice reverses muscle weakness and bone loss.